You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

albumin paclitaxel

Showing 1 - 25 of 4,283
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

Recruiting
  • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
  • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
  • Hanzhou, Zhejiang, China
    Lulu Liu
Jul 14, 2023

Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)

Not yet recruiting
  • Second Line Treatment of Gastric Cancer
  • (no location specified)
Dec 20, 2022

Locally Advanced Pancreatic Cancer Trial in Guangzhou (Sulfatinib, Serplulimab, Albumin-paclitaxel)

Not yet recruiting
  • Locally Advanced Pancreatic Cancer
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Aug 10, 2023

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)

Recruiting
  • Neoadjuvent
  • +3 more
  • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
  • Xi'an, Shaanxi, China
  • +2 more
Aug 17, 2023

Oral Squamous Cell Carcinoma Trial (Tislelizumab, Albumin paclitaxel, Cisplatin)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • (no location specified)
May 7, 2023

Gallbladder Cancer, Initially Unresectable, the First Line Treatment Trial in Shanghai (Combination of Gemcitabine,

Recruiting
  • Gallbladder Cancer
  • +2 more
  • Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 24, 2023

Esophageal Carcinoma, Neoadjuvant Therapy Trial (Toripalimab, Anlotinib HCl, Albumin paclitaxel)

Not yet recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Therapy
  • (no location specified)
Aug 16, 2023

Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Paclitaxel-albumin)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2023

Breast Tumor Female Trial (AK105, Anlotinib HCl, Albumin Paclitaxel)

Not yet recruiting
  • Breast Neoplasm Female
  • (no location specified)
Jul 11, 2022

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast

Not yet recruiting
  • To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
  • Monosialotetrahexose ganglioside sodium injection
  • (no location specified)
Mar 27, 2023

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

HER2-positive Breast Cancer Trial in Xi'an (Pyrotinib)

Recruiting
  • HER2-positive Breast Cancer
  • Xi'an, Shaanxi, China
    Jin Yang
Jun 18, 2022

Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

Not yet recruiting
  • Gastric Adenocarcinoma
  • cadonilimab combined +paclitaxel (albumin-bound)
  • (no location specified)
Nov 1, 2023

Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Xi'an, Shaanxi, China
    Hongxi Zhao
Sep 20, 2023

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Mucosal Melanoma Trial in China (YH003, Pembrolizumab, albumin paclitaxel)

Recruiting
  • Mucosal Melanoma
  • Fuzhou, Fujian, China
  • +11 more
Oct 8, 2022

Locally Advanced Gastric Cancer Trial in Fuzhou (Camrelizumab, Albumin Taxol, FLOT scheme)

Not yet recruiting
  • Locally Advanced Gastric Cancer
  • Fuzhou, Fujian, China
  • +1 more
Nov 8, 2022

Hypopharyngeal Cancer Trial (Cisplatin/Nedaplatin, albumin paclitaxel)

Not yet recruiting
  • Hypopharyngeal Cancer
  • Cisplatin/Nedaplatin, albumin paclitaxel
  • (no location specified)
May 5, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

HER2 Positive Non Resectable or Metastatic Breast Cancer Trial (SHR-A1811:Pyrroltinib, SHR-A1811;Pertuzumab, SHR-A1811;SHR-1316)

Not yet recruiting
  • HER2 Positive Non Resectable or Metastatic Breast Cancer
  • (no location specified)
Apr 25, 2022